GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » American Oncology Network Inc (OTCPK:AONCW) » Definitions » EV-to-EBITDA

American Oncology Network (American Oncology Network) EV-to-EBITDA : 0.00 (As of Jun. 19, 2024)


View and export this data going back to 2023. Start your Free Trial

What is American Oncology Network EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, American Oncology Network's enterprise value is $0.00 Mil. American Oncology Network's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-59.32 Mil. Therefore, American Oncology Network's EV-to-EBITDA for today is 0.00.

The historical rank and industry rank for American Oncology Network's EV-to-EBITDA or its related term are showing as below:

During the past 4 years, the highest EV-to-EBITDA of American Oncology Network was 9.54. The lowest was -56.83. And the median was -10.40.

AONCW's EV-to-EBITDA is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 12.52
* Ranked among companies with meaningful EV-to-EBITDA only.

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-19), American Oncology Network's stock price is $0.275. American Oncology Network's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $0.000. Therefore, American Oncology Network's PE Ratio for today is N/A.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


American Oncology Network EV-to-EBITDA Historical Data

The historical data trend for American Oncology Network's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

American Oncology Network EV-to-EBITDA Chart

American Oncology Network Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
- - - -8.97

American Oncology Network Quarterly Data
Dec20 Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial - - -35.68 -8.97 -5.12

Competitive Comparison of American Oncology Network's EV-to-EBITDA

For the Medical Care Facilities subindustry, American Oncology Network's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


American Oncology Network's EV-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, American Oncology Network's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where American Oncology Network's EV-to-EBITDA falls into.



American Oncology Network EV-to-EBITDA Calculation

American Oncology Network's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=0.000/-59.316
=0.00

American Oncology Network's current Enterprise Value is $0.00 Mil.
American Oncology Network's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-59.32 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


American Oncology Network  (OTCPK:AONCW) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

American Oncology Network's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.275/0.000
=N/A

American Oncology Network's share price for today is $0.275.
American Oncology Network's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


American Oncology Network EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of American Oncology Network's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


American Oncology Network (American Oncology Network) Business Description

Traded in Other Exchanges
Address
10485 NE 6th Street, Unit 3930, Bellevue, WA, USA, 98004
American Oncology Network Inc Formerly American Oncology Network LLC is an alliance of physicians and seasoned healthcare leaders who provide comprehensive oncology services through 24 oncology practices located in Arkansas, Louisiana, Indiana, Virginia, Ohio, Nevada, Iowa, Missouri, Washington, North Carolina, Michigan, Maryland, South Carolina, Arizona, and Georgia. The Company also provides expertise in drug procurement and payor contracting, along with practice diversification through centralized laboratory and pathology services, as well as specialty pharmacy services.